guipatsizet

Guipatsizet is a small molecule neuroprotective agent, typically developed as a maleate salt (guipatsizet maleate), for the treatment of acute ischemic stroke. It is a purified pharmaceutical composition derived from Gualoupi (the peel of *Trichosanthes kirilowii*), a traditional Chinese medicinal herb. Developed by Hunan Yige Pharmaceutical, the drug is intended to be administered via intravenous injection within the acute phase (typically within 48 hours) of a stroke to mitigate neuronal damage and improve clinical outcomes. Guipatsizet has progressed to Phase 3 clinical trials in China, where it is being evaluated for its efficacy and safety in a large patient population. It is classified as a Category 1.1 new drug in the Chinese regulatory system, representing a highly purified chemical entity or specific fraction derived from natural sources.

Other names

guipatsizet maleateGualoupiqizhiGualoupiqizhi maleate